Delving into the Latest Updates on Xi'an Lijun Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Other Diseases

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2
Nervous System Diseases	2
Neoplasms	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	5

Top 5 Target	Count

PR(Progesterone receptor)	1
PBPs(Bacterial penicillin-binding protein)	1
PDEs x TNF-α	1
50S subunit(50S ribosomal subunit)	1

按有关生物等效性试验的规定，选择ARBOR PHARMACEUTICALS LLC为持证商的琥乙红霉素颗粒（商品名：Eryped ®，规格：400mg/5mL）为参比制剂，对西安利君制药有限责任公司生产的受试制剂琥乙红霉素颗粒（商品名：利君沙，规格：0.1g/包）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，比较两种制剂在空腹给药条件下的生物等效性。

[Translation]

In accordance with the relevant provisions of bioequivalence tests, erythromycin ethylsuccinate granules (trade name: Eryped ®, specification: 400 mg/5 mL) manufactured by ARBOR PHARMACEUTICALS LLC was selected as the reference preparation, and the test preparation erythromycin ethylsuccinate granules (trade name: Lijunsha, specification: 0.1 g/bag) produced by Xi'an Lijun Pharmaceutical Co., Ltd. was subjected to a human bioequivalence test on fasting administration to compare whether the absorption rate and degree of the drug in the test preparation were within an acceptable range with those of the reference preparation, and to compare the bioequivalence of the two preparations under fasting administration conditions.

Start Date18 Dec 2021

Sponsor / Collaborator

Xi'an Lijun Pharmaceutical Co., Ltd.

CTR20213037

/ CompletedNot Applicable

琥乙红霉素颗粒（0.1g）在中国健康受试者中餐后给药条件下随机、开放、单剂量、四周期、完全重复交叉设计生物等效性试验

[Translation] A randomized, open-label, single-dose, four-period, completely repeated crossover bioequivalence study of erythromycin ethylsuccinate granules (0.1 g) in healthy Chinese subjects after meal administration

按有关生物等效性试验的规定，选择ARBOR PHARMACEUTICALS LLC为持证商的琥乙红霉素颗粒（商品名：Eryped ®，规格：400mg/5mL）为参比制剂，对西安利君制药有限责任公司生产的受试制剂琥乙红霉素颗粒（商品名：利君沙，规格：0.1g/包）进行餐后给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，比较两种制剂在餐后给药条件下的生物等效性。

[Translation]

According to the relevant provisions of bioequivalence test, erythromycin ethylsuccinate granules (trade name: Eryped ®, specification: 400mg/5mL) of ARBOR PHARMACEUTICALS LLC as the licensee was selected as the reference preparation, and the test preparation erythromycin ethylsuccinate granules (trade name: Lijunsha, specification: 0.1g/bag) produced by Xi'an Lijun Pharmaceutical Co., Ltd. was subjected to a human bioequivalence test after meal administration to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to compare the bioequivalence of the two preparations under the condition of postprandial administration.

Start Date01 Dec 2021

Sponsor / Collaborator

Xi'an Lijun Pharmaceutical Co., Ltd.

CTR20212854

/ CompletedNot Applicable

阿奇霉素胶囊（0.25g）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of azithromycin capsules (0.25 g) in Chinese healthy volunteers under fasting conditions

主要研究目的：按有关生物等效性试验的规定，选择普利瓦克罗地亚有限公司为生产商的阿奇霉素胶囊为参比制剂，对西安利君制药有限责任公司生产的受试制剂阿奇霉素胶囊进行空腹给药人体生物等效性试验。次要研究目的：观察健康志愿受试者口服受试制剂阿奇霉素胶囊和参比制剂阿奇霉素胶囊的安全性。

[Translation]

The main purpose of the study: According to the relevant provisions of the bioequivalence test, the azithromycin capsules produced by Pliva Croatia Co., Ltd. were selected as the reference preparation, and the human bioequivalence test of the test preparation azithromycin capsules produced by Xi'an Lijun Pharmaceutical Co., Ltd. was conducted on the fasting administration. The secondary purpose of the study: to observe the safety of the test preparation azithromycin capsules and the reference preparation azithromycin capsules in healthy volunteers.

Start Date26 Jul 2021

Sponsor / Collaborator

Xi'an Lijun Pharmaceutical Co., Ltd.

100 Clinical Results associated with Xi'an Lijun Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Xi'an Lijun Pharmaceutical Co., Ltd.

Login to view more data

4

Literatures (Medical) associated with Xi'an Lijun Pharmaceutical Co., Ltd.

Zhongguo Yaoye

Improvement of formulation of simvastatin tablets and quality assessment

Author: Gao, Xiang ; Zhang, Xuanjun ; Ma, Youfeng ; Wang, Weifeng ; Li, Fang

The formulation of simvastatin tablets was improved.The simvastatin capsules were made by polyacrylic resin IV.The formulation and preparation of simvastatin tablets were identified via screening disintegrant and other excipients.The problems of oxidation and unstability was solved.L-hydroxypropyl cellulose and sodium carboxymethyl starch was used as disintegrant.The new formulation is reasonable and new technol. is feasible.

Xibei Yaoxue Zazhi

Homocysteine and health of aged people

Author: Liu, Yan-hong ; Wang, Hong-juan

A review.Homocysteine (Hcy) is a new research focus in recent years.Hyperhomocysteinmia is an important absolute risk factor of early and genetic cardiovascular diseases.This paper reviewed the generation and therapy of hyperhomocysteinemia, and the relationship of high Hcy and cardiovascular and cerebrovascular diseases, Alzheimer's disease, and migraine.

Shipin Gongye Keji

Preservation and insect control of daylily

Author: An, Na

Using daylily in Qingyang, Gansu Province as raw material, the effect of temperature, packaging, and pest control (NaHSO₃) on the preservation and insect control of daylily were studied.The best option to inhibit browning was 28°C, not vacuum sealed, NaHSO₃ 0.5%.

100 Deals associated with Xi'an Lijun Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Xi'an Lijun Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Amoxicillin Trihydrate ( PBPs )	Bacterial Infections More	Approved
Sinomenine hydrochloride	Inflammation More	Approved
Clarithromycin ( 50S subunit )	Lower Respiratory Tract Infections More	Approved
Pentoxifylline ( PDEs x TNF-α )	Peripheral arterial occlusive disease More	Approved
Medroxyprogesterone Acetate ( PR )	Breast Cancer More	Approved